BackMonte Rosa Therapeutics Overview

Monte Rosa Therapeutics Other Assets

Latest other assets for GLUE: $0.

Get informed when a big investor buys or sells

+ Follow
Other Assets
$0.00

Peer average / median

Loading

Monte Rosa Therapeutics Other Assets History

Loading

Monte Rosa Therapeutics vs. peers: Other Assets Comparison

Loading

Monte Rosa Therapeutics Other Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Monte Rosa Therapeutics (GLUE) FAQ

As of the most recent data (June 2026), GLUE shows a other assets of $0. In the prior-year period, the figure was $0. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, GLUE's other assets is now $0 (was $0). Pairing that YoY change with peer averages gives a clearer picture of whether Monte Rosa Therapeutics is outperforming or lagging.

Tracking GLUE's other assets over time shows whether Monte Rosa Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $0 In the prior-year period, the figure was $0. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this other assets page, Stockcircle has Monte Rosa Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect other assets (currently $0) with ownership activity and broader fundamentals.

Monte Rosa Therapeutics's other assets is $0; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.